Logo image of CALA

CALITHERA BIOSCIENCES INC (CALA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CALA - US13089P5070 - Common Stock

0.3651 USD
-0.04 (-10.95%)
Last: 2/1/2023, 8:04:28 PM
0.3401 USD
-0.02 (-6.85%)
After Hours: 2/1/2023, 8:04:28 PM
Fundamental Rating

3

Overall CALA gets a fundamental rating of 3 out of 10. We evaluated CALA against 530 industry peers in the Biotechnology industry. While CALA seems to be doing ok healthwise, there are quite some concerns on its profitability. CALA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CALA has reported negative net income.
CALA had a negative operating cash flow in the past year.
CALA Yearly Net Income VS EBIT VS OCF VS FCFCALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M -80M -100M

1.2 Ratios

CALA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CALA Yearly ROA, ROE, ROICCALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

CALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALA Yearly Profit, Operating, Gross MarginsCALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

CALA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CALA has less shares outstanding than it did 1 year ago.
CALA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CALA Yearly Shares OutstandingCALA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
CALA Yearly Total Debt VS Total AssetsCALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

CALA has an Altman-Z score of -27.42. This is a bad value and indicates that CALA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CALA (-27.42) is worse than 91.98% of its industry peers.
CALA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.42
ROIC/WACCN/A
WACC9.19%
CALA Yearly LT Debt VS Equity VS FCFCALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.76 indicates that CALA has no problem at all paying its short term obligations.
CALA has a Current ratio of 3.76. This is in the lower half of the industry: CALA underperforms 66.98% of its industry peers.
CALA has a Quick Ratio of 3.76. This indicates that CALA is financially healthy and has no problem in meeting its short term obligations.
CALA's Quick ratio of 3.76 is on the low side compared to the rest of the industry. CALA is outperformed by 65.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.76
CALA Yearly Current Assets VS Current LiabilitesCALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

CALA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.17%, which is quite impressive.
The Revenue for CALA has decreased by -100.00% in the past year. This is quite bad
The Revenue for CALA have been decreasing by -24.04% on average. This is quite bad
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CALA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.34% on average per year.
The Revenue is expected to grow by 120.38% on average over the next years. This is a very strong growth
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CALA Yearly Revenue VS EstimatesCALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2025 2026 2027 200M 400M 600M 800M
CALA Yearly EPS VS EstimatesCALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CALA. In the last year negative earnings were reported.
Also next year CALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALA Price Earnings VS Forward Price EarningsCALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALA Per share dataCALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

CALA's earnings are expected to grow with 23.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.25%
EPS Next 3Y23.9%

More info and screens

0

5. Dividend

5.1 Amount

CALA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALITHERA BIOSCIENCES INC

NASDAQ:CALA (2/1/2023, 8:04:28 PM)

After market: 0.3401 -0.02 (-6.85%)

0.3651

-0.04 (-10.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)03-29 2023-03-29/amc
Inst OwnersN/A
Inst Owner Change100%
Ins Owners111.41%
Ins Owner Change0%
Market Cap1.78M
Revenue(TTM)N/A
Net Income(TTM)-83.56M
Analysts84
Price Target5.1 (1296.88%)
Short Float %0.14%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.48%
Min EPS beat(2)-2.28%
Max EPS beat(2)41.23%
EPS beat(4)3
Avg EPS beat(4)11.38%
Min EPS beat(4)-2.28%
Max EPS beat(4)41.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.12%
EPS NQ rev (1m)11.13%
EPS NQ rev (3m)11.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-205.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)-12
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-12.48
FCFYN/A
OCF(TTM)-12.45
OCFYN/A
SpS0
BVpS5.42
TBVpS5.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.76
Altman-Z -27.42
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)23.75%
Cap/Depr(5y)88.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33%
EPS Next Y69.34%
EPS Next 2Y38.25%
EPS Next 3Y23.9%
EPS Next 5Y14.34%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.04%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.38%
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24%
OCF growth 3YN/A
OCF growth 5YN/A

CALITHERA BIOSCIENCES INC / CALA FAQ

What is the fundamental rating for CALA stock?

ChartMill assigns a fundamental rating of 3 / 10 to CALA.


Can you provide the valuation status for CALITHERA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 3 / 10 to CALITHERA BIOSCIENCES INC (CALA). This can be considered as Overvalued.


How profitable is CALITHERA BIOSCIENCES INC (CALA) stock?

CALITHERA BIOSCIENCES INC (CALA) has a profitability rating of 0 / 10.


How financially healthy is CALITHERA BIOSCIENCES INC?

The financial health rating of CALITHERA BIOSCIENCES INC (CALA) is 2 / 10.